Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM
A H E Herbers1, W J F M van der Velden1, A F J de Haan2
1Department of Haematology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Bone Marrow Transplantation
|August 20, 2013
Abstract:
The matched-control study failed to show a clinical relevant impact of palifermin on intestinal mucositis, although there was a reduced inflammatory response and less febrile neutropenia among patients who had no bacteraemia.
